Overview of Prostate Anatomy, Histology, and Pathology

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 3, 2011, Pages 565-575

  Lee, Christine H ^a   Akin Olugbade, Oluyemi ^a   Kirschenbaum, Alexander ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Adenocarcinoma; Androgen receptor; Mouse model; Prostate; Prostatic intraepithelial neoplasia

Indexed keywords

ACID PHOSPHATASE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; CYTOKERATIN 18; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; VERY LATE ACTIVATION ANTIGEN 2;

ANATOMICAL CONCEPTS; ANATOMICAL VARIATION; BASAL CELL; BLADDER; CANCER GROWTH; CANCER STAGING; CELL DIFFERENTIATION; CELL POPULATION; COLUMNAR EPITHELIUM; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVIEW; SEMINAL VESICLE; STROMA;

ADENOCARCINOMA; ANDROGENS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 80052212356     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.05.012     Document Type: Review

References (24)

1. McNeal J.E., Bostwick D.G., Kindrachuk R.A., et al. Patterns of progression in prostate cancer. Lancet 1986, 1:60.
2. McNeal J.E. The prostate and prostatic urethra: a morphologic synthesis. J Urol 1972, 107:1008.
3. Shappell S.B., Thomas G.V., Roberts R.L., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004, 64:2270-2305.
4. Harmelin A., Danon T., Kela I., et al. Biopsy of the mouse prostate. Lab Anim 2005, 39(2):215-220.
5. Roy-Burman P., Wu H., Powell W.C., et al. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr Relat Cancer 2004, 11:225-254.
6. McNeal J.E. Origin and development of carcinoma in the prostate. Cancer 1969, 23(1):24-34.
7. Bostwick D.G., Brawer M.K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987, 59(4):788-794.
8. Kovi J., Jackson M.A., Heshmat M.Y. Ductal spread in prostatic carcinoma. Cancer 1985, 56(7):1566-1573.
9. McNeal J.E., Reese J.H., Redwine E.A., et al. Cribiform adenocarcinoma of the prostate. Cancer 1986, 58:1714.
10. Gleason D.F. The Veterans Administration Cooperative Research Group: histologic grading and clinical staging of prostatic carcinoma. Urologic pathology: the prostate 1977, 171-198. Philadelphia, Lee and Febiger. M. Tannenbaum (Ed.).
11. Epstein J.I., Allsbrook W.C., Amin M.B., et al. The 2005 International Society of Urologic Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2000, 24:477.
12. Epstein J.I. An update of the Gleason grading system. J Urol 2010, 183(2):433-440.
13. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl 1989, 2:33-50.
14. Heer R., Robson C.N., Shenton B.K., et al. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J Cell Physiol 2007, 212(3):572-578.
15. Kirschenbaum A., Liu X.H., Yao S., et al. Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones. Carcinogenesis 2005, 27(2):216-224.
16. Goldstein A.S., Huang J., Guo C., et al. Identification of a cell of origin for human prostate cancer. Science 2010, 329(5991):568-571.
17. Kasper S., Sheppard P.C., Yan Y., et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 1998, 78(6):i-xv.
18. Masumori N., Thomas T.Z., Chaurand P., et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001, 61(5):2239-2249.
19. Greenberg N.M., DeMayo F., Finegold M.J., et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995, 92(8):3439-3443.
20. Gingrich J.R., Barrios R.J., Kattan M.W., et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997, 57(21):4687-4691.
21. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55(3):219-237.
22. Stanbrough M., Leav I., Kwan P.W., et al. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A 2001, 98(19):10823-10828.
23. Majumder P.K., Yeh J.J., George D.J., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 2003, 100(13):7841-7846.
24. Wang S., Gao J., Lei Q., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4(3):209-221.